Life Long Learning Prep Course: Module 1 Webcast (2020): Testicular Cancer & Penile/Urethral Cancer
Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
The purpose of the Life Long Learning Prep Course: A Focused Review is to prepare attendees for the ABU knowledge assessment. This course will be practice-focused and will offer practical and clinically-specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the knowledge assessment. The course will model the changes to the ABU exam by covering Core/General Urology on the first day followed by Module 1: Oncology, Urinary Diversion and Adrenal on the second day.
Sample multiple choice practice questions as well as case-based discussions will be utilized to prepare attendees for the upcoming knowledge assessment. For more information on the changes to the exam, please visit www.abu.org/recertification.
At the conclusion of this course, participants will be able to:
- Discuss the appropriate indications for and use diagnostic tests in the management of urologic cancers.
- Enhance ability to make guideline-based decisions regarding management of common urologic cancers.
- Recognize and execute appropriate measures to prevent and manage complications resulting for management intervention for urologic cancers.
- Develop and employ a disease stage appropriate surveillance schedule during post management follow-up of urologic cancers.
|Module 1: Oncology, Urinary Diversion and Adrenal|
Moderator: Mark L. Gonzalgo, MD, PhD
|Presented Live on Sunday, September 13, 2020|
|Welcome: Mark L. Gonzalgo, MD, PhD|
|Urothelial Bladder Cancer: Siamak Daneshmand, MD|
|Prostate Cancer – Localized: Mark L. Gonzalgo, MD, PhD|
|Testicular Cancer: Chad R. Ritch, MD, MBA|
|Penile/Urethral Cancer: Chad R. Ritch, MD, MBA|
|Upper Tract Tumors/Urinary Diversion: Siamak Daneshmand, MD|
|Kidney Cancer: Viraj A. Master, MD, PhD, FACS|
|Adrenal: Viraj A. Master, MD, PhD, FACS|
|Prostate Cancer – Advanced: Mark L. Gonzalgo, MD, PhD|
|Mock Multiple Choice Exam and Review: All Faculty|
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.75 hours
Release Date: September, 2020
Expiration Date: September, 2023
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.75 AMA PRA Category 1 Credit™
- 1.75 Non-Physician Participation